Literature DB >> 28042506

MicroRNA-613 suppresses proliferation, migration and invasion of osteosarcoma by targeting c-MET.

Xinyu Li1, Xufang Sun1, Jing Wu2, Zhihong Li3.   

Abstract

MicroRNA-613 (miR-613) has been reported to play an important role in the pathogenesis of multiple cancers by negatively regulating gene expression at posttranscriptional level. However, the biological role of miR-613 in osteosarcoma (OS) remained unclear. In this study, we aimed to determine the expression and biological roles of miR-613 in OS. We found that miR-613 was significantly downregulated in OS tissues and cell lines, and that decreased miR-613 expression was correlated negatively with advanced TNM stage and lymph node metastasis. Overexpression of miR-613 in OS cells significantly suppressed the proliferation and colony formation by regulating cell arrest at G0/G1 phase, and impaired the migration and invasive abilities of OS cells, followed by suppression of the epithelial mesenchymal transition (EMT). Bioinformatic and luciferase reporter analysis identified cellular-mesenchymal to epithelial transition factor (c-MET, also named as MET) as a direct target of miR-613. Overexpression of miR-613 significantly inhibited the c-MET expression and its downstream PI3k/Akt/mTOR signaling pathway in OS cells. In OS clinical samples, there was a significant inverse correlation between miR-613 and c-MET mRNA expression. Rescue experiments showed that overexpression of c-MET partially prevented miR-613-induced suppression of OS cell proliferation, colony formation, migration and invasion. In conclusion, we provide first evidence for the suppressive activity of miR-613 by repressing c-MET, suggesting that miR-613 might be a potential therapeutic strategy for OS.

Entities:  

Keywords:  c-MET; invasion; miR-613; migration; osteosarcoma; proliferation

Year:  2016        PMID: 28042506      PMCID: PMC5199760     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  32 in total

Review 1.  microRNA functions.

Authors:  Natascha Bushati; Stephen M Cohen
Journal:  Annu Rev Cell Dev Biol       Date:  2007       Impact factor: 13.827

Review 2.  The Met pathway: master switch and drug target in cancer progression.

Authors:  Massimiliano Mazzone; Paolo M Comoglio
Journal:  FASEB J       Date:  2006-08       Impact factor: 5.191

3.  MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.

Authors:  Yingmin Yao; Chanwei Dou; Zhongtang Lu; Xin Zheng; Qingguang Liu
Journal:  Cell Physiol Biochem       Date:  2015-02-02

4.  Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.

Authors:  Kelai Wang; Yan Zhuang; Chunlan Liu; Yang Li
Journal:  Arch Biochem Biophys       Date:  2012-07-20       Impact factor: 4.013

5.  Osteosarcoma in preadolescent patients.

Authors:  M Rytting; P Pearson; A K Raymond; A Ayala; J Murray; A W Yasko; M Johnson; N Jaffe
Journal:  Clin Orthop Relat Res       Date:  2000-04       Impact factor: 4.176

6.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

7.  HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.

Authors:  Maria Trovato; Maria Luisa Torre; Marta Ragonese; Angela Simone; Rosy Scarfì; Valeria Barresi; Giuseppe Giuffrè; Salvatore Benvenga; Flavio F Angileri; Giovanni Tuccari; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Salvatore Cannavò
Journal:  Endocrine       Date:  2013-04-11       Impact factor: 3.633

Review 8.  c-Met as a Target for Personalized Therapy.

Authors:  Ingrid Garajová; Elisa Giovannetti; Guido Biasco; Godefridus J Peters
Journal:  Transl Oncogenomics       Date:  2015-11-23

9.  miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.

Authors:  Qing-Yong Chen; De-Min Jiao; Jian Wang; Huizhen Hu; Xiali Tang; Jun Chen; Hao Mou; Wei Lu
Journal:  Oncotarget       Date:  2016-04-26

10.  MicroRNA-613 inhibits cell growth, migration and invasion of papillary thyroid carcinoma by regulating SphK2.

Authors:  Wangwang Qiu; Zhili Yang; Youben Fan; Qi Zheng
Journal:  Oncotarget       Date:  2016-06-28
View more
  17 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.

Authors:  Qiying Yao; Li Zhang; Yuchuan Wang; Junli Liu; Liu Yang; Yingjie Wang
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

3.  LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer.

Authors:  Huihua Cai; Jie Yao; Yong An; Xuemin Chen; Weibo Chen; Di Wu; Boyang Luo; Yong Yang; Yong Jiang; Donglin Sun; Xiaozhou He
Journal:  Oncotarget       Date:  2017-05-16

Review 4.  NutrimiRAging: Micromanaging Nutrient Sensing Pathways through Nutrition to Promote Healthy Aging.

Authors:  Víctor Micó; Laura Berninches; Javier Tapia; Lidia Daimiel
Journal:  Int J Mol Sci       Date:  2017-04-26       Impact factor: 5.923

5.  Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs.

Authors:  Chih-Yen Tu; Fang-Ju Cheng; Chuan-Mu Chen; Shu-Ling Wang; Yu-Chun Hsiao; Chia-Hung Chen; Te-Chun Hsia; Yu-Hao He; Bo-Wei Wang; I-Shan Hsieh; Yi-Lun Yeh; Chih-Hsin Tang; Yun-Ju Chen; Wei-Chien Huang
Journal:  Mol Oncol       Date:  2018-04-14       Impact factor: 6.603

6.  CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613.

Authors:  Yong Zhu; Lanhua Tang; Shushan Zhao; Buhua Sun; Liang Cheng; Yifu Tang; Zhongwei Luo; Zhangyuan Lin; Jianxi Zhu; Weihong Zhu; Ruibo Zhao; Bangbao Lu; Haitao Long
Journal:  Cancer Sci       Date:  2018-06-26       Impact factor: 6.716

7.  MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.

Authors:  Weixin Xie; Jie Xiao; Tao Wang; Dongmei Zhang; Zhanchun Li
Journal:  J Cell Mol Med       Date:  2019-02-17       Impact factor: 5.310

8.  Role of miR-613 as a tumor suppressor in glioma cells by targeting SOX9.

Authors:  Qiuling Sang; Xuejuan Liu; Daju Sun
Journal:  Onco Targets Ther       Date:  2018-04-30       Impact factor: 4.147

9.  LncRNA LINC00152 Increases the Aggressiveness of Human Retinoblastoma and Enhances Carboplatin and Adriamycin Resistance by Regulating MiR-613/Yes-Associated Protein 1 (YAP1) Axis.

Authors:  Ying Wang; Danli Xin; Lei Zhou
Journal:  Med Sci Monit       Date:  2020-06-15

10.  LncRNA HOTAIR/miR-613/c-met axis modulated epithelial-mesenchymal transition of retinoblastoma cells.

Authors:  Ge Yang; Yang Fu; Xiaoyan Lu; Menghua Wang; Hongtao Dong; Qiuming Li
Journal:  J Cell Mol Med       Date:  2018-07-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.